S&P 500
3,351.28+2.12(+0.06%)Nasdaq
11,010.98-97.12(-0.87%)Russell 2000
1,569.18+24.56(+1.59%)
NanoString Technologies, Inc. (NSTG)
Chart Events
Performance Outlook
| Previous Close | 36.04 |
| Open | 36.00 |
| Bid | 32.08 x 900 |
| Ask | 38.08 x 1000 |
| Day's Range | 34.51 - 36.73 |
| 52 Week Range | 13.85 - 38.40 |
| Volume | 303,249 |
| Avg. Volume | 472,073 |
| Market Cap | 1.33B |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.60 |
| Earnings Date | Aug 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.50 |
- Zacks
Medical Products Stock Earnings on Aug 10: CGC, SDGR & More
Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.
- Business Wire
NanoString and Bio-Techne Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler
NanoString Expands RNAscope Partnership with Bio-Techne's ACD Division.
- PR Newswire
Bio-Techne And NanoString Announce Offering Of RNAscope Reagents Validated For Use With The GeoMx Digital Spatial Profiler
Bio-Techne (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic markets and NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced an expansion of their partnership to include compatibility with ACD's 21,000+ RNAscope probes and 10 qualified RNAscope probe combinations with GeoMx® Digital Spatial Profiler (DSP) and the recently launched GeoMx Cancer Transcriptome Atlas (CTA).
